ArticleACS pharmacology & translational science2025
Olfactory Drug Delivery in Rodents: Deposition and Pharmacokinetics.
Article in ACS pharmacology & translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Imaging of intranasal drug delivery to the brain: updated review 2.0.Drug delivery and translational research · 2026Review
- Intranasal Drug Delivery in Neuropharmacology: Advances in Brain-Targeted Therapies and Bioethical Challenges.Biomedicines · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Olfactory drug delivery (ODD) is a route of administration that precisely targets the olfactory cleft, a region of the upper nasal cavity with privileged access to the brain. ODD offers better brain delivery compared to traditional intranasal (IN) delivery (e.g., nasal spray), which has imprecise, off-target drug deposition to the lower nasal cavities, with very little (if any) deposition at the olfactory region. ODD has immense potential for the noninvasive delivery of medication to the brain for the treatment of mental health and neurological disorders. Previously, we defined successful ODD as deposition of at least 50% of a dose to the olfactory cleft compared to the surrounding nasal cavities, assessed with a nasal endoscope. In this study, we investigate whether ODD is associated with increased brain uptake and compare the ODD, IN, and intravenous (IV) routes of administration across a range of compounds. First, using positron emission tomography (PET) imaging in rats, we demonstrate that ODD consistently targets the olfactory cleft, facilitating the brain uptake of fluorodeoxyglucose and fluorothymidine (FLT). These results successfully replicate previous work demonstrating direct nose-to-brain delivery of the poor blood-brain barrier penetrating molecule FLT. Additionally, we evaluated compounds that were selected for diversity of physiological properties and indications and demonstrated that for certain molecules, ODD offers superior brain delivery compared to IN and IV and demonstrates greater consistency than traditional IN administration. Remarkably, the volume of liquid required for ODD is approximately an order of magnitude smaller than that for the IN or IV methods, reducing variability in dosing, off-target deposition, and cost. These findings suggest that adopting the ODD method could enhance the accuracy, precision, and reproducibility of dosing across intranasal drug delivery applications. Importantly, ODD offers a consistent (less variable), accurate, and targeted method for improving the deliverability of medication to the brain.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.